- Home
- NLSP vs ACON Comparison
NLSP vs ACON Comparison
Compare NLSP & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- ACON
- Stock Information
- Founded
- NLSP 2015
- ACON 2008
- Country
- NLSP Switzerland
- ACON United States
- Employees
- NLSP N/A
- ACON N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- NLSP Health Care
- ACON Technology
- Exchange
- NLSP Nasdaq
- ACON Nasdaq
- Market Cap
- NLSP 5.9M
- ACON 4.8M
- IPO Year
- NLSP 2021
- ACON 2022
- Fundamental
- Price
- NLSP $1.50
- ACON $7.64
- Analyst Decision
- NLSP
- ACON Buy
- Analyst Count
- NLSP 0
- ACON 2
- Target Price
- NLSP N/A
- ACON $481.00
- AVG Volume (30 Days)
- NLSP 102.5K
- ACON 75.1K
- Earning Date
- NLSP 05-14-2025
- ACON 04-09-2025
- Dividend Yield
- NLSP N/A
- ACON N/A
- EPS Growth
- NLSP N/A
- ACON N/A
- EPS
- NLSP N/A
- ACON N/A
- Revenue
- NLSP N/A
- ACON $45,724.00
- Revenue This Year
- NLSP N/A
- ACON $251.35
- Revenue Next Year
- NLSP N/A
- ACON N/A
- P/E Ratio
- NLSP N/A
- ACON N/A
- Revenue Growth
- NLSP N/A
- ACON N/A
- 52 Week Low
- NLSP $1.30
- ACON $7.26
- 52 Week High
- NLSP $18.40
- ACON $6,241.05
- Technical
- Relative Strength Index (RSI)
- NLSP 49.86
- ACON 33.40
- Support Level
- NLSP $1.38
- ACON $8.15
- Resistance Level
- NLSP $1.53
- ACON $8.30
- Average True Range (ATR)
- NLSP 0.09
- ACON 1.25
- MACD
- NLSP 0.02
- ACON 6.41
- Stochastic Oscillator
- NLSP 64.91
- ACON 6.94
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.